KAT5

Across TCGA pan-cancer cohorts, KAT5 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated KAT5 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KAT5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KAT5 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

BLCA, BRCA, and ESCA are the cancer types where KAT5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.526	0.720	<.001	14	view →
BRCA	OS	Median	All	0.107	0.578	<.001	12	view →
ESCA	OS	Median	All	0.198	0.872	.003	12	view →
LIHC	OS	Median	All	0.226	0.773	.008	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
ACC	DFS	Median	All	0.089	0.666	.010	9	view →
GBM	OS	Median	All	0.030	0.416	<.001	6	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
HNSC	DFS	Median	All	0.286	0.628	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

KAT5–BLCA (OS)

Open the BLCA breakdown →